Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia.

Nicola GökbugetHervé DombretSebastian GiebelMonika BrüggemannMichael DoubekRobin FoaDieter HoelzerChristopher KimGiovanni MartinelliElena ParovichnikovaJosep Maria RiberaMarieke SchoonenCatherine TuglusGerhard ZugmaierRenato Bassan

Published in: European journal of haematology (2020)

These analyses suggest that blinatumomab improves RFS, and possibly OS, in adults with MRD-positive Ph-negative BCP-ALL vs SOC.

Keyphrases

acute lymphoblastic leukemia
healthcare
liver failure
palliative care
respiratory failure
quality improvement
drug induced
pain management
combination therapy
health insurance